Amsterdam, Brussels, Dublin, Lisbon, London and Paris –  18 October 2018 – Euronext today announced the 2019 trading days for its markets in Amsterdam, Brussels, Dublin, Lisbon, London and Paris.

Euronext’s Cash and Derivatives markets will be open Monday to Friday throughout 2019 except on the following days:

• Tuesday 1 January 2019 (New Year’s Day)
• Friday 19 April 2019 (Good Friday)
• Monday 22 April 2019 (Easter Monday)
• Wednesday 1 May 2019 (Labour Day)
• Wednesday 25 December 2019 (Christmas Day)
• Thursday 26 December 2019 (Boxing Day)

On Tuesday 24 December 2019 (Christmas Eve) and on Tuesday 31 December 2019 (New Year’s Eve), trading on the Cash Markets, including Euronext Dublin, will be half day trading with all instruments closing by 14:05 CET. Contracts on the Derivatives Markets will close at various times, commencing at 13:55 CET.

This 2019 holiday calendar will also apply to Euronext Dublin markets from the migration date, set on 4^th February 2019, pending regulatory approval.

As some other markets have not yet published their trading schedules for next year, more detailed information on the trading of relevant derivatives contracts and Euronext Block will be published in due course. Information can also be found at www.euronext.com/trading-calendars-hours.

€628 million raised; market capitalisation €1.4 billion

Paris – 17 October 2018 – Euronext today welcomed Neoen, France’s leading independent producer of exclusively renewable energy and one of the sector’s most dynamic businesses worldwide, to Compartment A of its regulated market in Paris. This was the largest IPO in Paris in 16 months, and the largest clean-tech IPO in Europe this year.

An active player in the energy transition and the fight against climate change, Neoen is an independent producer of renewable energy that has expanded rapidly in France and on international markets in Europe, Australia, North and South America, and Africa. Founded in 2008, the company develops, owns and operates land-based solar parks and wind farms. Its assets include one of Europe’s largest solar parks, in Cestas in southwestern France (Gironde), generating 300 megawatts. Listing will enable the company to finance further growth. Neoen was recognised as a “future unicorn” at the 2018 Trophée des Futures Licornes ceremony organised by Entreprenur Venture, Euronext, EM Lyon business school, Roland Berger and Reputation Age.

Neoen (ticker code: NEOEN) was listed on 17 October 2018 through the admission to trading of 84,919,998 shares representing its entire capital, including 38,073,521 shares allocated[1] as part of a Global Offering^[2], before potential exercise of the over-allotment option.  

The offering price was set at €16.50 per share. Market capitalisation on the day of listing was around €1.4 billion, and the operation raised a total of €628 million.

At the listing ceremony, Xavier Barbaro, Chairman and CEO of Neoen, said: “We are very proud of our successful market debut. Neoen is the first French unicorn specialising in renewable energies to list on Euronext Paris, and the market’s largest listing in the past 16 months. In particularly demanding market conditions, this reflects great confidence in our strategy, our positioning and our growth potential. We would like to extend warm thanks to our shareholders, old and new, and to our workforce, our advisers, and Euronext Paris, who helped make our listing a success.”

Lisbon, 16 October 2018 – Euronext today welcomed Farminveste SGPA, SA (“Farminveste”) on  Euronext Access in Lisbon.

Farminveste is an investment company whose corporate objective is to invest in companies in the areas of pharmaceutical distribution, information technology and systems, pharmaceutical market intelligence, provision of healthcare services and real estate. Its main shareholder  is the Portuguese National Pharmacies Association whose membership comprises almost all pharmacies in Portugal. Other shareholders include several Portuguese Pharmacies.

The listing of Farminveste highlights the ambition of the company and its long-term objectives, enhancing its domestic and international profile and reputation. It also demonstrates the core mission of Euronext to finance the real economy, giving companies the visibility and the access to a wide range of investors, and also access to capital.

Paulo Jorge Cleto Duarte, CEO of Farminveste, said: “The admission to trading of Farminveste B shares on the Euronext Access platform is a significant step towards the consolidation of the Farminveste group's growth. Its main objective is to enable investors to have a mechanism that facilitates the transaction of the company's shares and the establishment of a reference price for them. It is also an additional guarantor of credibility and transparency for the market."

Farminveste (ticker symbol: MLFMV) was listed through the admission to trading of 9,500,000 B-shares through a technical listing on 16 October 2018The company’s market capitalisation on the day of its listing was €53 million considering only the listed B-shares.

Euronext Access is a gateway market for companies seeking simplified access to listing and improved visibility. It is open to companies of all sizes, maturities or industries.

_{About Farminveste
Farminveste – Investimentos, Participações e Gestão, S.A. ("Farminveste") is an investment company whose corporate object is to invest in companies in the areas of pharmaceutical distribution, information technology and systems, pharmaceutical market intelligence, provision of healthcare services and real estate. It is owned by the Portuguese National Pharmacies Association whose membership comprisesalmost all pharmacies in Portugal. For more information please visit: www.farminveste-sgps.com}

Pioneer of self-storage in Europe raises €575 million, making it the second largest newly-listed company to join Euronext Brussels over the last decade

Brussels, 15 October 2018 – Shurgard Self Storage SA (“Shurgard”, ticker symbol: SHUR) today began trading on Euronext Brussels (Compartment A) with an initial market capitalisation of €2.04 billion.

Shurgard is the largest owner and operator of self-storage centers (stores) in Europe in terms of number of stores and net rentable square meters. Shurgard commenced operations in 1995 and is one of the pioneers of the self-storage concept in Europe. In total, its network of 229 stores comprises approximately 1.2 million net rentable square meters and serves more than 150,000 customers in the Netherlands, France, Sweden, the United Kingdom, Belgium, Germany and Denmark.

With an Offer Price at €23 per share, Shurgard’s total offering size amounts to €575 million. With a total of 88,935,681 shares admitted to trading, Shurgard has an initial market capitalisation before opening of €2.04 billion.

Marc Oursin, CEO of Shurgard, said: “With the ringing of the Euronext Brussels bell, we are starting a new chapter in our company’s history. Still, our core value will always remain the same: to provide the best storage experience for our customers and to further strengthen our platform of self-storage centers with growth across the 7 countries where we operate.” 

To mark Shurgard’s first trading day, Marc Oursin, CEO, rang the bell to open the markets in Brussels today.
 

€30 million raised; market capitalisation €144 million

Paris – 8 October 2018 – Euronext today welcomed MedinCell, a pharmaceutical technology company that develops injectable drug delivery solutions, to listing in compartment C of Euronext Paris. 

Based in Jacou, near Montpellier in southern France, MedinCell is dedicated to achieving significant gains in the efficiency of drug therapies. The two most advanced products in its pipeline, designed to treat schizophrenia and post-operative orthopedic pain, respectively, are now in Phase III and Phase II clinical trials in the United States. Its seven other products treat a range of conditions including depression, chronic pain and contraception—all areas where MedinCell’s patented BEPO® technology is likely to change conditions fundamentally.

MedinCell (ticker code: MEDCL) was listed on 8 October 2018 through the admission to trading of 19,878,372 shares making up its capital, including 4,137,931 new shares issued through a Global Offering^[1] before potential exercise of the over-allotment option and 1,258,841 shares issued in exchange for convertible bonds.

The offering price was set at €7.25 per share. Market capitalisation on the day of listing was around €144 million, and the operation raised a total of €30 million.

At the listing ceremony, Christophe Douat, Chairman of MedinCell’s Executive Board, said: “Today’s listing is a milestone for MedinCell. It confirms the expertise and tenacity of the entire MedinCell team, and illustrates the strength of our approach, in which all of our staff members are either already shareholders or will have that opportunity. This is one key to our success—a success that includes two products already in Phase II and III clinical trials in the United States, with ten more in the pipeline. The funds we’ve raised will enable us to expand our portfolio and increase our impact on global health. I would like to take this opportunity to thank all our team members who have been working hard to this end, as well as the new shareholders who have joined us and who share our goals, including our vision of harnessing pharmaceuticals to serve human well-being, and our commitment to a better world.”